17-Beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease

Flavio Airoldi, Carlo Di Mario, Flavio Ribichini, Patrizia Presbitero, Paolo Sganzerla, Valeria Ferrero, Corrado Vassanelli, Carlo Briguori, Mauro Carlino, Matteo Montorfano, Giuseppe G L Biondi-Zoccai, Alaide Chieffo, Angela Ferrari, Antonio Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

In this study we randomly compared the estradiol eluting stent (17-β-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-β-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-β-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-β-E eluting stent over the control PC stent.

Original languageEnglish
Pages (from-to)664-667
Number of pages4
JournalThe American Journal of Cardiology
Volume96
Issue number5
DOIs
Publication statusPublished - Sep 1 2005

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of '17-Beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease'. Together they form a unique fingerprint.

Cite this